🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

President and CEO,Dr. Paul Peter Tak, MD, PhD, FMedSci, CSO Francesca Barone, MD, PhD, and VP of Finance & Corporate Controller, Charles Schoch are kicking off 2024 at the 42nd Annual J.P. Morgan Healthcare conference. Be sure to say hello! #JPMorgan2024 #JPM24

Posting comments about the interpretation of clinical trial data comes with a responsibility to get it absolutely right, especially as it relates to cancer patients who are urgently waiting for better treatments. Let's dissect why this post was misleading. A thread.

Safe and feasible intratumoral CAN-2409 delivery on outpatient basis can reinvigorate immune response in ICI refractory #NSCLC and extend survival. Charu Aggarwal, MD, MPH, FASCO Perlmutter Cancer Center at NYU Langone Health NYU Langone Health #ASCO24

Late stage melanoma represents a life threatening unmet clinical need. Come and visit our poster during SITC to discuss our plans to leverage our first in class viral immunotherapy CAN-3110 to fight this terrible disease.

linkedin.com/posts/francesc…

We hope we will deliver the data and regulatory approvals in prostate cancer to enable a paradigm shift in how these patients will be treated in the future. #CandelTherapeutics #viral #immunotherapy #CAN-2409 $CADL proactiveinvestors.com/companies/news…

x.com/i/article/1867…

Adam Feuerstein ✡️ Candel Therapeutics Manufacturing. While we continued to advance analytical development and comparability studies successfully, and locked the process, we did not want to spend tens of millions of $$ on large scale manufacturing before data read out - a concept that we call dynamic portfolio

linkedin.com/posts/francesc…

Molecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome nature.com/articles/s4146… Nature Communications Francesca Barone

The collaboration between Candel Therapeutics and IDEA Pharma comes at a critical time as we prepare for our BLA submission for CAN-2409 in prostate cancer. Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and

Combination of surgical upfront immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab for newly diagnosed glioblastoma (Wen et al. March 2025, SNO). E. Antonio Chiocca, MD, PhD, FAANS & Dr. Paul Peter Tak

New in SNO! Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety & survival data with immune activation supporting CAN-2409's pan-tumor potential. Read more: ir.candeltx.com/news-releases/… $CADL

Candel Therapeutics is set to host a webcast and conference call on Tuesday, June 3, 2025, at 1:00 PM ET. The event will delve into the promising phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer. These results showcased a notable 30%

Join our investor conference call on Tuesday, June 3 at 1:00 PM ET following our #ASCO25 presentation. Our management team & leading prostate cancer specialists will discuss our phase 3 CAN-2409 results. Find more details here: ir.candeltx.com/news-releases/… $CADL #ProstateCancer

Great day for ⁦Candel Therapeutics⁩ !!!! linkedin.com/posts/francesc…